Digostics

Digostics is a UK-based digital clinical diagnostics company founded in 2019 by CEO James Jackson, along with co-founders Hugo Tewson and Gita Sorenson. Jackson, a biochemist and immunologist with experience in the diagnostics and life science sectors since the mid-1980s, conceived the company's core product. The company's mission is to improve the detection of diabetes by providing accessible testing solutions.

The primary service is GTT@home, the first regulatory-approved at-home oral glucose tolerance test (OGTT). This product is a diagnostic solution-as-a-service designed to replace in-clinic testing. The business model involves selling GTT@home kits directly to healthcare providers, such as the UK's National Health Service (NHS), where it is listed on the NHS Supply Chain. Revenue is generated from these sales, with an established and growing pipeline within the NHS.

The GTT@home kit includes a simple-to-use device with two glucose test sensors, a glucose drink, and finger prickers. It performs a standard OGTT by taking a fasting capillary sample and a second sample two hours after the glucose drink. An onboard timer ensures correct test intervals, and the device instantly analyzes the samples, mitigating the risk of sample degradation common in clinical settings. Patients can transmit their results to their care team via NFC using a mobile application. The service is initially focused on detecting gestational diabetes but is also being piloted for Type 1 and Type 2 diabetes screening. Digostics has expanded internationally, establishing operations in the UAE and Singapore to drive early market engagement.

Keywords: at-home diagnostics, diabetes testing, oral glucose tolerance test, OGTT, GTT@home, medtech, digital health, remote patient monitoring, gestational diabetes, point-of-care testing, medical devices, clinical diagnostics, diabetes screening, telemedicine, healthcare technology, preventative medicine, glucose monitoring, CE-marked device, diagnostic services, health equity